TSN084

Tyligand Bioscience (Shanghai) Limited · Phase 1 active Small molecule

At a glance

Generic name	TSN084
Sponsor	Tyligand Bioscience (Shanghai) Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TSN084 Treating Patients With Advanced Malignant Tumors (PHASE1)
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TSN084 CI brief — competitive landscape report
TSN084 updates RSS · CI watch RSS
Tyligand Bioscience (Shanghai) Limited portfolio CI